SA
TWST icon

Strategic Advocates’s Twist Bioscience TWST Stock Holding History

Strategic Advocates’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.6K Buy
1,760
+693
+65% +$31.1K 0.37% 59
2025
Q4 		$34.3K Buy
1,067
+906
+563% +$28.3K 0.01% 232
2025
Q3 		$4.53K Buy
+161
New +$4.88K ﹤0.01% 421

Other funds holding TWST

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Strategic Advocates's TWST Position: Q1 2026 in Review

Strategic Advocates increased its Twist Bioscience (TWST) stake by 65% in Q1 2026, buying an estimated $31.1K and bringing the position to 1,760 shares worth $83.6K. The position accounts for 0.37% of the portfolio, ranked #59.

Strategic Advocates first reported a position in TWST in Q3 2025 and has held it in 3 quarters since. 279 funds tracked by Wall St. Rank hold TWST as of Q1 2026.

  • Strategic Advocates held 1,760 shares of Twist Bioscience worth $83.6K as of Q1 2026.
  • Strategic Advocates bought 693 Twist Bioscience shares in Q1 2026, an estimated $31.1K.
  • Twist Bioscience made up 0.37% of Strategic Advocates's portfolio in Q1 2026, its #59 holding.
  • Strategic Advocates first reported a position in Twist Bioscience in Q3 2025 and has held it in 3 quarters since.
  • 279 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.